Cisplatin-treated macrophages produce oncostatin M: regulation by serine/threonine and protein tyrosine kinases/phosphatases and Ca2+/calmodulin
- PMID: 9698114
- DOI: 10.1016/s0165-2478(98)00040-6
Cisplatin-treated macrophages produce oncostatin M: regulation by serine/threonine and protein tyrosine kinases/phosphatases and Ca2+/calmodulin
Abstract
In the present study it was investigated whether cisplatin-treated murine peritoneal macrophages produce oncostatin M (OSM) and what is the underlying mechanism. The culture supernatants of cisplatin-treated macrophages significantly inhibited the proliferation of OSM-sensitive cell line A375. Within 15 min of cisplatin treatment significant OSM was synthesized and secreted by macrophages. Inhibitors of serine/threonine and protein tyrosine phosphatases augmented cisplatin-induced OSM production of macrophages. The protein kinase C and protein tyrosine kinase inhibitors significantly inhibited OSM production of cisplatin-treated macrophages. The OSM production of cisplatin-treated macrophages was also inhibited in the presence of Ca2+ chelators, Ca2+ channel blocker and calmodulin/calmodulin-dependent kinase inhibitors. These data suggest that OSM production of cisplatin-treated macrophages is regulated by opposing actions of phosphatases and kinases. It is also suggested that OSM production of cisplatin-treated macrophages is dependent on Ca2+, calmodulin and calmodulin-dependent kinase.
Similar articles
-
Expression and activation of lyn in macrophages treated in vitro with cisplatin: regulation by kinases, phosphatases and Ca2+/calmodulin.Biochim Biophys Acta. 1998 Oct 21;1405(1-3):171-9. doi: 10.1016/s0167-4889(98)00106-2. Biochim Biophys Acta. 1998. PMID: 9784629
-
Expression and activation of RAS and mitogen-activated protein kinases in macrophages treated in vitro with cisplatin: regulation by kinases, phosphatases and Ca2+/calmodulin.Immunol Cell Biol. 1999 Aug;77(4):356-63. doi: 10.1046/j.1440-1711.1999.00841.x. Immunol Cell Biol. 1999. PMID: 10457204
-
LFA-1-dependent tumoricidal activity of cisplatin-treated macrophages.Immunol Cell Biol. 1998 Aug;76(4):343-9. doi: 10.1046/j.1440-1711.1998.00751.x. Immunol Cell Biol. 1998. PMID: 9723775
-
Regulation of the activities of multifunctional Ca2+/calmodulin-dependent protein kinases.J Biochem. 2001 Feb;129(2):193-9. doi: 10.1093/oxfordjournals.jbchem.a002843. J Biochem. 2001. PMID: 11173518 Review.
-
Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases.J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S57-61. J Am Soc Nephrol. 1999. PMID: 9892141 Review.
Cited by
-
The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.Breast Cancer Res. 2019 Apr 29;21(1):54. doi: 10.1186/s13058-019-1136-x. Breast Cancer Res. 2019. PMID: 31036052 Free PMC article.
-
Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.Cancer Res. 2021 Oct 15;81(20):5336-5352. doi: 10.1158/0008-5472.CAN-21-0483. Epub 2021 Aug 11. Cancer Res. 2021. PMID: 34380633 Free PMC article.
-
Cancer Stem Cell Plasticity Drives Therapeutic Resistance.Cancers (Basel). 2016 Jan 5;8(1):8. doi: 10.3390/cancers8010008. Cancers (Basel). 2016. PMID: 26742077 Free PMC article. Review.
-
HiJAK'd Signaling; the STAT3 Paradox in Senescence and Cancer Progression.Cancers (Basel). 2014 Mar 26;6(2):741-55. doi: 10.3390/cancers6020741. Cancers (Basel). 2014. PMID: 24675570 Free PMC article.
-
Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling.Oncogene. 2017 Jul 13;36(28):4001-4013. doi: 10.1038/onc.2017.33. Epub 2017 Mar 13. Oncogene. 2017. PMID: 28288136 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous